Search

News Thinking About Idiopathic Pulmonary Fibrosis?

Idiopathic pulmonary fibrosis (IPF) is one of the most prognostically severe and difficult-to-treat lung diseases. It affects about 5 million people worldwide, with an estimated incidence in the Czech Republic of 1/100,000 inhabitants. Although it is a relatively rare disease, due to its high mortality rate (the median survival of untreated patients is 2−3 years), it is essential to have a basic awareness of the possible symptoms of IPF. Expert sources even state that, according to statistics, only pancreatic cancer leads to a faster death compared to untreated pulmonary fibrosis.

Source: Pulmonary Fibrosis 16. 4. 2020

News Development of Albuminuria During Treatment with ACE Inhibitors and Sartans

Individual molecules from the class of renin-angiotensin system inhibitors display various distinct properties at the molecular level, and their renoprotective potential may differ. A study by Korean authors observed the development of renal parameters in individuals with albuminuria during the first 3 months after the initiation of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs), also known as sartans.

Source: Sartans in the Treatment of Hypertension 25. 5. 2020

News Regular Walking as an Intervention to Support the Quality of Life of Diabetics

Diabetes mellitus (DM), as a chronic and in many cases disabling disease, limits patients in various aspects of their lives. Therefore, it is important to consider the quality of life of diabetics as part of treatment and to seek ways to appropriately support it and enable patients to be as actively involved in everyday life as possible. The American journal Diabetes Care published the results of a study evaluating the impact of regular walking on the quality of life in DM.

Source: Diabetes 25. 2. 2020

News Impact of Sacubitril/Valsartan Treatment on Left Ventricular Reverse Remodeling

A meta-analysis evaluated the effect of sacubitril/valsartan on echocardiographic parameters (not only) in patients with HFrEF. The authors focused on both the presence and significance of changes, as well as the speed of their onset after the initiation of treatment.

Source: Chronic Heart Failure and Lipidology 1. 6. 2020

Články časopisu Management of autoinflammatory diseases: Czech-Slovak adaptation of the SHARE European recommendations*

Author of the article: Š. Fingerhutová, T. Dallos, K. Bouchalova, I. Brejchová, J. Fráňová, E. Jančová, K. Jarošová, K. Kobrová, M. Macků, H. Malcová, L. Minxová, D. Němcová, M. Schüller, E. Skalická, V. Vargová, Doležalová P. Pro Pracovní Skupiny Dětské Revmatologie Při Čps, Sps Source: Česko-slovenská pediatrie | 4/2018 30. 8. 2018

News Orally Administered Berotralstat in the Prevention of Hereditary Angioedema Attacks

Berotralstat is an oral medication administered once daily, developed to prevent hereditary angioedema (HAE) attacks. It is a kallikrein protease inhibitor, which plays a key role in the pathogenesis of this disease. A phase III clinical trial, with results recently published in the Journal of Allergy and Clinical Immunology, evaluated the efficacy and safety of two dosing regimens of berotralstat compared to placebo in patients with HAE.

Source: Hereditary Angioedema 25. 2. 2022

News Comparison of EHL Products in the Treatment of Hemophilia A –⁠ Pharmacoeconomic Analysis

In the work presented below, whose results were recently published, a model combining pharmacokinetic and pharmacodynamic data was developed. With its help, the authors tried to compare the bleeding rates in hemophiliacs treated with various EHL products. At the same time, they focused on the cost-effectiveness of this treatment.

Source: Hemophilia with Movement 21. 5. 2021

News Position of Generic Drugs in Oncology: What Are Their Main Advantages?

Generics –⁠ as is well known –⁠ are products containing the same active substance as the original medicinal product, which can enter the market after the patent protection of the original drug has expired. They are applied in various medical fields, including oncology. The main goal of producing generics is to improve the accessibility of treatment for a wide range of patients while maintaining the safety and effectiveness of the therapy.

Source: Oncological Treatment 15. 9. 2021

News Position of Enoxaparin and DOACs in Extended Prevention of VTE After Surgeries for Gynecological Malignancies

The prophylaxis of venous thromboembolism is a crucial part of postoperative management in oncological diseases, including gynecological malignancies. A newly published survey study conducted in Australia and New Zealand focused precisely on these. The authors were interested in different types of postoperative prophylactic regimens and the potential use of direct oral anticoagulants (DOACs) in them.

Source: Thromboprophylaxis 3. 1. 2024

News With Dr. Miroslav Nečas, Ph.D., on the conclusions of the recent consensus of the expert panel on the practice of biological treatment of psoriasis

This February, an expert consensus on the use of bimekizumab in the treatment of psoriasis and psoriatic arthritis (PsA) was published based on a literature review of 102 articles, from which 19 relevant publications were selected. A panel of 9 dermatologists then voted to accept 14 consensus statements and recommendations, 12 of which received an 'A' grade, one a 'B' grade, and one a 'C' grade. We discuss key conclusions and recommendations with Dr. Miroslav Nečas, Ph.D., from the 1st Department of Dermatovenereology at MU and St. Anne's Faculty Hospital in Brno.

Source: Rheumatic Diseases 19. 6. 2024

News Impact of Alpha-1 Antitrypsin Deficiency on Quality of Life and Mental Health of Patients

The clinical manifestation of alpha-1 antitrypsin deficiency and its impact on quality of life are highly heterogeneous. This contribution by pulmonologist Robert Sandhaus summarizes interesting findings from studies on the quality of life of patients with this disease and the factors influencing it.

Source: Deficiency of Alpha-1-Antitrypsin 3. 11. 2020

News Can alpha-1-antitrypsin deficiency affect severity and higher mortality in COVID-19 patients?

Alpha-1-antitrypsin (AAT) deficiency is commonly found in the European population. The most cases are recorded in countries with the highest COVID-19 mortality rates. Are there direct correlations?

Source: Deficiency of Alpha-1-Antitrypsin 12. 4. 2021

News Efficacy of Brigatinib in Patients with Metastatic NSCLC −⁠ Real-World Clinical Data

The journal Lung Cancer published the results of a retrospective analysis of the efficacy of brigatinib in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who participated in a European early access treatment program.

Source: Non-Small Cell Lung Cancer 29. 11. 2021

News Curative Potential of Neoadjuvant Denosumab in the Treatment of Giant Cell Spinal Tumor? A Case Study

Portuguese authors present a case study of a young woman diagnosed with a giant cell spinal tumor who achieved complete histological remission following denosumab treatment.

Source: Prevention of Bone Events 9. 4. 2022

News The Anti-inflammatory and Renoprotective Effect of Candesartan May Be Independent of the AT1 Receptor

Candesartan belongs to the blockers of AT1 receptors (AT1R) for angiotensin II coupled with G protein. The authors of the presented study found that the anti-inflammatory and renoprotective effect of candesartan persists even when the receptor is completely blocked. The aim of the further study was to clarify this mechanism -⁠ independent of AT1R.

Source: Sartans in the Treatment of Hypertension 12. 8. 2021